Back to Authors

Dong, Jie

https://orcid.org/0000-0002-8148-3838

Mayo Clinic

Mayo Clinic

Citations 5

Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors
Thomas, Charles F., Dong, Jie , Schulte, Sandra C., Khadka, Prasidda , Sun, Zhifu , Kosari, Farhad , Jen, Jin , Molina, Julian R. , Vasmatzis, George , Kuang, Ray, Aubry, Marie Christine, Wigle, Dennis A. , Asiedu, Michael K. , Molina, Julian, Sun, Zhifu , Yang, Ping

Clinical Cancer Research | January 19, 2018 | Volume: 24 | Issue: 7 | Pages: 1691-1704

10.1158/1078-0432.ccr-17-0252 Get It

Abstract Purpose: Pulmonary carcinoid tumors account for up to 5% of all lung malignancies in adults, comprise 30% of all carcinoid malignancies, and are defined histologically as typical carcinoid (TC) and atypical carcinoid (AC) tumors. The role of specific genomic alterations in the pathogenesis of pulmonary carcinoid tumors remains poorly understood. We sought to identify genomic alterations and pathways that are deregulated in these tumors to find novel therapeutic targets for pulmonary carcinoid tumors. Experimental Design: We performed integrated genomic analysis of carcinoid tumors comprising whole genome and exome sequencing, mRNA expression profiling and SNP genotyping of specimens from normal lung, TC and AC, and small cell lung carcinoma (SCLC) to fully represent the lung neuroendocrine tumor spectrum. Results: Analysis of sequencing data found recurrent mutations in cancer genes including ATP1A2, CNNM1, MACF1, RAB38, NF1, RAD51C, TAF1L, EPHB2, POLR3B, and AGFG1. The mutated genes are involved in biological processes including cellular metabolism, cell division cycle, cell death, apoptosis, and immune regulation. The top most significantly mutated genes were TMEM41B, DEFB127, WDYHV1, and TBPL1. Pathway analysis of significantly mutated and cancer driver genes implicated MAPK/ERK and amyloid beta precursor protein (APP) pathways whereas analysis of CNV and gene expression data suggested deregulation of the NF-κB and MAPK/ERK pathways. The mutation signature was predominantly C>T and T>C transitions with a minor contribution of T>G transversions. Conclusions: This study identified mutated genes affecting cancer relevant pathways and biological processes that could provide opportunities for developing targeted therapies for pulmonary carcinoid tumors. Clin Cancer Res; 24(7); 1691–704. ©2018 AACR.
Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases
Fritchie, Karen , Jin, Long , Graham, Rondell P. , Lewis, Jean E., Rivera, Michael , García, Joaquín J., Schembri‐Wismayer, David, Chou, Margaret M. , Dong, Jie , Oliveira, André M. , Fritchie, Karen J. , Wang, Xiaoke, Schembri-Wismayer, David J, Wang, Xiaoke, Torbenson, Michael , Westendorf, Jennifer J. , Graham, Rondell P

Histopathology | July 25, 2016 | Volume: 69 | Issue: 6 | Pages: 930-936

10.1111/his.13045 Get It

AimsBiphenotypic sinonasal sarcoma (SNS) is a locally aggressive tumour that occurs in the sinonasal region. PAX3–MAML3 has recently been identified as a recurrent fusion gene event in this entity; however, a subset of tumours harbour alternative PAX3 rearrangement without the involvement of MAML3. In this study we sought to characterize the molecular profile of a large series of cases, with a special emphasis on tumours with alternative fusions.Methods and resultsForty‐four examples of SNS were screened by fluorescence in‐situ hybridization and reverse transcription polymerase chain reaction to better characterize its molecular profile and identify potential novel fusion genes. Twenty‐four were positive for PAX3–MAML3 (55%), 15 showed rearrangements of PAX3 without MAML3 involvement (34%), one showed rearrangement of MAML3 without PAX3 involvement, and four were negative for the involvement of either gene (9%). Among 15 cases with PAX3 involvement only, three were found to harbour PAX3–FOXO1. Two of these cases arose in the nasal cavities of female patients (aged 31 and 47 years), and one showed bilateral involvement of the nasal cavities of a 35‐year‐old male. A fourth case involved the skull base of a 47‐year‐old male, and was positive for PAX3–NCOA1. Patients with fusion‐negative tumours were slightly older.ConclusionMore than half of the SNSs in this series were positive for PAX3–MAML3. However, a subset of tumours may harbour alternative PAX3 fusion genes or show no involvement of PAX3. Except for a possible weak association between age and molecular profile, the overall morphological and immunophenotypic features of all cases seem to be similar. Because of the rarity of these tumours, the impact of the molecular profile on the clinical course of these tumours remains to be determined.
PPP6R3‐USP6 amplification: Novel oncogenic mechanism in malignant nodular fasciitis
Guo, Ruifeng, Chou, Margaret M. , Asmann, Yan W. , Wenger, Doris E. , Al‐Ibraheemi, Alyaa , Molavi, Diana Weedman, Aboulafia, Albert J. , Jin, Long , Fritchie, Karen , Oliveira, Jennifer L. , Jenkins, Robert B. , Dong, Jie , Oliveira, André M. , Guo, Ruifeng , Herrick, Jennifer L. , Wang, Xiaoke, Asmann, Yan, Al-Ibraheemi, Alyaa, Guo, Ruifeng, Wang, Xiaoke, Westendorf, Jennifer J. , Guo, Ruifeng

Genes, Chromosomes and Cancer | April 27, 2016 | Volume: 55 | Issue: 8 | Pages: 640-649

10.1002/gcc.22366 Get It

Nodular fasciitis (NF) is a clonal self‐limited neoplastic proliferation characterized by rearrangements of the USP6 locus in most examples. To our knowledge well‐documented malignant behavior has never been previously observed in NF. In this report we present an unusual case of NF with classical histologic features that showed a protracted clinical course characterized by multiple recurrences and eventual metastatic behavior over a period of 10 years. Molecular analyses revealed the presence and amplification of the novel PPPR6‐USP6 gene fusion, which resulted in USP6 mRNA transcriptional upregulation. These findings further support the oncogenic role of the USP6 protease in mesenchymal neoplasia and expand the biologic potential of NF. © 2016 Wiley Periodicals, Inc.
MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion
Tomaszek, Sandra, Kosari, Farhad , Metintaş, Muzaffer , Jett, James R., Metintaş, Selma , Yıldırım, Hüseyin , Dündar, Emine , Dong, Jie , Aubry, Marie Christine, Wigle, Dennis A. , Thomas, Charles F., Tomaszek, Sandra C, Ak, Güntülü

BioMed Research International | February 1, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-8

10.1155/2015/635748 Get It

Introduction. We investigated the expression of microRNAs and mRNAs in pleural tissues from patients with either malignant pleural mesothelioma or benign asbestos-related pleural effusion.Methods. Fresh frozen tissues from a total of 18 malignant pleural mesothelioma and 6 benign asbestos-related pleural effusion patients were studied. Expression profiling of mRNA and microRNA was performed using standard protocols.Results. We discovered significant upregulation of multiple microRNAs in malignant pleural mesothelioma compared to benign asbestos-related pleural effusion. Hsa-miR-484, hsa-miR-320, hsa-let-7a, and hsa-miR-125a-5p were able to discriminate malignant from benign disease. Dynamically regulated mRNAs were also identified. MET was the most highly overexpressed gene in malignant pleural mesothelioma compared to benign asbestos-related pleural effusion. Integrated analyses examining microRNA-mRNA interactions suggested multiple altered targets within the Notch signaling pathway.Conclusions. Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma.
Hyperoxia-induced changes in estradiol metabolism in postnatal airway smooth muscle
Martin, Yvette N. , Manlove, L., Dong, Jie , Carey, William A., Pandya, Hitesh , Martin, Richard J. , Wigle, Dennis A. , Prakash, Y. S. , Manlove, Logan, Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S

American Journal of Physiology-Lung Cellular and Molecular Physiology | November 15, 2014 | Volume: 308 | Issue: 2 | Pages: L141-L146

10.1152/ajplung.00266.2014 Get It

Supplemental oxygen, used to treat hypoxia in preterm and term neonates, increases the risk of neonatal lung diseases, such as bronchopulmonary dysplasia (BPD) and asthma. There is a known sex predilection for BPD, but the underlying mechanisms are not clear. We tested the hypothesis that altered, local estradiol following hyperoxia contributes to pathophysiological changes observed in immature lung. In human fetal airway smooth muscle (fASM) cells exposed to normoxia or hyperoxia, we measured the expression of proteins involved in estrogen metabolism and cell proliferation responses to estradiol. In fASM cells, CYP1a1 expression was increased by hyperoxia, whereas hyperoxia-induced enhancement of cell proliferation was blunted by estradiol. Pharmacological studies indicated that these effects were attributable to upregulation of CYP1a1 and subsequent increased metabolism of estradiol to a downstream intermediate 2-methoxyestradiol. Microarray analysis of mouse lung exposed to 14 days of hyperoxia showed the most significant alteration in CYP1a1 expression, with minimal changes in expression of five other genes related to estrogen receptors, synthesis, and metabolism. Our novel results on estradiol metabolism in fetal and early postnatal lung in the context of hyperoxia indicate CYP1a1 as a potential mechanism for the protective effect of estradiol in hyperoxia-exposed immature lung, which may help explain the sex difference in neonatal lung diseases.